Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab

by | May 14, 2019 | Dermatological, immunology, Other Conditions, Publication

Abstract Authors: Knight T, Bond C, Popelar B, Wang L, Niewoehner J, Anastassopoulos K, Philbin M. Background: Dermatomyositis and polymyositis (DM/PM) are rare, incurable inflammatory diseases that cause progressive muscle weakness and can be associated with...

Evaluating the Effect of Treatment Persistence on the Economic Burden of Moderate to Severe Psoriasis and/or Psoriatic Arthritis Patients in the US Department of Defense Population

by | May 13, 2019 | immunology, Publication

Abstract Authors: Lee S, Xie L, Wang Y, Vaidya N, Baser O. Background: Psoriasis is a chronic, hyper-proliferative dermatological condition associated with joint symptoms known as psoriatic arthritis (PsA). In a 2013 review, the total economic burden of PsA was...

Treatment persistence and clinical outcomes of TNFi cycling or switching to a new mechanism of action therapy: Real-world observational study of rheumatoid arthritis patients in the United States with prior TNF therapy

by | May 11, 2019 | immunology, Publication

Abstract Authors: Wei W, Knapp K, Wang L, Chen CI, Craig GL, Ferguson K, Schwartzman S Introduction: To examine treatment persistence and clinical outcomes associated with switching from a tumor necrosis factor inhibitor (TNFi) to a medication with a new...

Predicting pre-emptive discussions of biologic treatment: Results from an openness and preference survey of inflammatory bowel disease patients and their prescribers

by | May 9, 2019 | Gastrointestinal, immunology, Publication

Abstract Authors: Kariburyo F, Xie L, Teeple A, Tan H, Ingham M. Introduction: It is important to compare patient and provider discrepancies on stated openness to and preference for biologics as well as predictors associated with initial discussions on biologic...